

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

O9/771,302 01/26/2001			FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	7656	
			Martha J. Whitehouse	1543.201 (5784-81A)		
:	7590 08/07	7/2002	•			
Chiron Corporation			•	EXAMINER		
4560 Horton Street Emeryville, CA 94608		•	· :	DEBERRY, REGINA M		
Emery vine, C	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			ART UNIT	PAPER NUMBER	
				1647		
				DATE MAILED: 08/07/2002	1/	

Please find below and/or attached an Office communication concerning this application or proceeding.

_	Application No	plication No. Applicant(s)					
	09/771,302		WHITEHOUSE, MARTHA J.				
Office Action Summary	Examiner		Art Unit				
	Regina M. DeB	<u> </u>	1647				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status							
1) Responsive to communication(s) filed on 16 M	<i>l</i> lay 2002 .						
2a) ☐ This action is FINAL . 2b) ☑ Thi	is action is non-	-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims							
4) Claim(s) <u>1-34</u> is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6) Claim(s) is/are rejected.							
7) Claim(s) is/are objected to.							
8) Claim(s) <u>1-34</u> are subject to restriction and/or e	ection require	ment.					
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) All b) Some * c) None of:							
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	4) [5) [6) [Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152)				

Application/Control Number: 09/771,302

Art Unit: 1647

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - Claims 1-9, drawn to FGF-2 composition, classified in class 530, subclass 350.
 - II. Claims 10-25, drawn to a method for treating a human patient for coronary artery disease, classified in class 514, subclass 2.
 - III. Claims 26-29, drawn to a method for inducing angiogenesis in a heart of a human patient, classified in class 514, subclass 2.
 - IV. Claims 30-34, drawn to a method for treating a human patient for a myocardial infarction, classified in class 514, subclass 2.
- 2. Inventions I and II-IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the methods of treating coronary artery disease, angiogenesis in the heart and myocardial infarction (Groups II, III and IV respectively) can be practiced with another product. Furthermore, the product of Group I can be used in processes to make antibodies.

Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. §806.05 for inventive groups that are directed to <u>different</u> methods, restriction is deemed to be proper because these methods appear to

Art Unit: 1647

constitute patentably distinct inventions for the following reasons: Groups II-IV are directed to methods that recite structurally and functionally distinct elements, are not required one for the other, and/or achieve different goals. The inventions of Groups II-IV encompass diverse patient populations. The Groups require search and consideration of different heart conditions and a technique, which may not overlap. A search on coronary artery disease (deposition of lipids in the inner layer of arterial walls) exhibits a different pathology versus myocardial infarction (deprivation of blood supply). Furthermore, the method of inducing angiogenesis involves the formation of blood vessels. Therefore, a search and examination of the methods in one patent application would result in an undue burden, since the searches for the methods are not coextensive, the classification is different, and/or the subject matter is divergent.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, separate search requirements, and/or recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Regina M. DeBerry whose telephone number is (703) 305-6915. The examiner can normally be reached on Mondays-Fridays 8:00 a.m. - 4:30 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz can be reached on (703) 308-4623. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-7939 for regular communications and (703) 308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

RMD

July 27, 2002

ELIZABETH KEMMERER PRIMARY EXAMINER

Elyabet C. Kenne